JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Galectin Therapeutics Inc

Geschlossen

BrancheGesundheitswesen

5.2 1.96

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

5.13

Max

5.25

Schlüsselkennzahlen

By Trading Economics

Einkommen

2.1M

-7.5M

Gewinnspanne

-33,241.667

Angestellte

15

EBITDA

4.5M

-5.7M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+14.72% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

13. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

80M

326M

Vorheriger Eröffnungskurs

3.24

Vorheriger Schlusskurs

5.2

Nachrichtenstimmung

By Acuity

26%

74%

51 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bullish Evidence

Galectin Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

24. Okt. 2025, 18:41 UTC

Ergebnisse

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

24. Okt. 2025, 18:31 UTC

Ergebnisse

Correction to Procter & Gamble to Focus on Innovation

24. Okt. 2025, 16:25 UTC

Wichtige Markttreiber

Obook Shares Rise, Company Secures New Money Transmitter Licenses

24. Okt. 2025, 21:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24. Okt. 2025, 21:24 UTC

Market Talk

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24. Okt. 2025, 21:07 UTC

Ergebnisse

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24. Okt. 2025, 20:58 UTC

Ergebnisse

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24. Okt. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

24. Okt. 2025, 20:40 UTC

Ergebnisse

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24. Okt. 2025, 20:24 UTC

Ergebnisse

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24. Okt. 2025, 20:23 UTC

Ergebnisse

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24. Okt. 2025, 20:13 UTC

Ergebnisse

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24. Okt. 2025, 20:07 UTC

Market Talk

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24. Okt. 2025, 19:40 UTC

Market Talk

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24. Okt. 2025, 19:35 UTC

Market Talk

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24. Okt. 2025, 19:33 UTC

Ergebnisse

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

24. Okt. 2025, 19:29 UTC

Market Talk

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

24. Okt. 2025, 18:52 UTC

Ergebnisse

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24. Okt. 2025, 18:41 UTC

Ergebnisse

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24. Okt. 2025, 18:03 UTC

Ergebnisse

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

24. Okt. 2025, 18:02 UTC

Ergebnisse

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

24. Okt. 2025, 18:00 UTC

Market Talk

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

24. Okt. 2025, 16:57 UTC

Ergebnisse

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

24. Okt. 2025, 16:54 UTC

Market Talk

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

24. Okt. 2025, 16:44 UTC

Market Talk
Ergebnisse

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

24. Okt. 2025, 16:39 UTC

Market Talk
Ergebnisse

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

24. Okt. 2025, 16:33 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24. Okt. 2025, 16:23 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24. Okt. 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

24. Okt. 2025, 16:07 UTC

Ergebnisse

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Peer-Vergleich

Kursveränderung

Galectin Therapeutics Inc Prognose

Kursziel

By TipRanks

14.72% Vorteil

12-Monats-Prognose

Durchschnitt 6 USD  14.72%

Hoch 6 USD

Tief 6 USD

Basierend auf 1 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Galectin Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

1 ratings

1

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

1.19 / 1.33Unterstützung & Widerstand

Kurzfristig

Very Strong Bullish Evidence

Mittelfristig

Weak Bullish Evidence

Langfristig

Weak Bearish Evidence

Stimmung

By Acuity

51 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Galectin Therapeutics Inc

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
help-icon Live chat